Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 13/20 | 0.58 |
| ▸ | RARG | P13631 | 13/20 | 0.58 |
| ▸ | RARA | P10276 | 12/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9006923 | 0.89 | RARB (0.46) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL19034088 | 0.88 | RARB (0.62) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL16913398 | 0.85 | RARB (0.56) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7652461 | 0.82 | RARA (0.42) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7650773 | 0.80 | RARA (0.40) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL8197282 | 0.79 | RARA (0.50) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL4309215 | 0.79 | RARA (0.50) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7217365 | 0.79 | RARA (0.50) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL29576948 | 0.79 | RARA (0.50) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL3300659 | 0.79 | RARB (0.55) | RARBRARGRARACYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| WO-2015107542-A2 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| WO-2009116075-A2 | PROCESS FOR PREPARATION OF TAZAROTENE | INDOCO REMEDIES LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | PPIA, CUTA, TFPI | RARB 130/4885RARG 294/4885RARA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.